An Innovative Molecular Fusion Format That Targets Ion Channel-Driven Diseases

Maxion是一家新成立的英国治疗开发SME，通过其新颖的颠覆性平台解决了重大的未满足的全球需求，该平台可以生成针对离子通道驱动疾病的抗体样治疗药物。从大自然中获得灵感，Maxion的创始人将在毒液和其他来源中发现的离子通道调节微型蛋白质（称为结蛋白）结合到抗体表面，创造出名为“结体”的混合物。结体结合了这两种成分的优点，既保留了结蛋白的离子通道调节功能，又具有抗体的最佳药物特性。Maxion独特的药物形式将用于治疗慢性疼痛、自身免疫性疾病和心脏病等疾病。这一创新产品将最初的药物发现时间缩短了至少两年，并将产生功能性离子通道调节剂的机会增加了10倍。

Maxion is a newly founded UK therapeutic development SME solving a significant unmet global need with its novel, disruptive platform that can generate antibody-like therapeutics to target ion channel-driven diseases. Taking inspiration from nature, Maxion's founders have combined ion channel modulating mini-proteins found in venom and other sources called knottins into the antibody surface to create mixtures named KnotBodies. KnotBodies combine the best of both components by preserving the ion channel modulating function of knottins while enjoying the optimum drug like properties of antibodies. Maxion's unique drug format will treat diseases such as chronic pain, autoimmune disorders and heart disease. This innovative product reduces initial drug discovery timelines by at least two years and increases the chance of generating a functional ion channel modulator by 10-fold.